Skip to main content
LYSOGENE logo

LYSOGENE — Investor Relations & Filings

Ticker · LYS ISIN · FR0013233475 LEI · 969500T64RILK1RD0852 PA Professional, scientific and technical activities
Open in API
Filings indexed 254 across all filing types
Latest filing 2021-03-31 Earnings Release
Country FR France
Listing PA LYS

About LYSOGENE

https://www.lysogene.com

Lysogene was a clinical-stage biotechnology company that specialized in the research and development of gene therapies for rare, inherited neurodegenerative diseases affecting the central nervous system (CNS). The company's approach focused on delivering a functional copy of a deficient gene directly to the brain to address the root cause of the targeted disorder. Its pipeline included investigational treatments for lysosomal storage diseases such as Sanfilippo syndrome type A (MPS IIIA) and GM1 gangliosidosis. Following clinical and financial challenges, the company initiated judicial liquidation proceedings in 2023.

Recent filings

Filing Released Lang Actions
Inside Information / News release on accounts, results
Earnings Release Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces the company's "Full Year 2020 Financial Results and Provides Operational Update." It contains key financial highlights (Income statement table, Net cash figures) and management commentary, which are characteristic of an Earnings Release (ER). While it covers the full year, it is presented as a press release announcing the results, rather than the comprehensive, audited 10-K filing itself. The date of the announcement is March 31, 2021, reporting on the 2020 fiscal year. This format strongly aligns with the definition of an Earnings Release (ER), which is the initial announcement of periodical financial results (key highlights only). It is not a full 10-K, nor is it a short announcement merely pointing to an attached report (RPA/RNS). FY 2020
2021-03-31 English
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 1% confidence The document is titled 'COMMUNIQUE DE PRESSE' (Press Release) and announces the company's 'résultats annuels 2020' (annual results for 2020) as of December 31, 2020. It includes a summary of key financial data (income statement, cash flow) for the year ended 2020 compared to 2019, management commentary, and updates on clinical programs. This structure—a formal announcement summarizing the full year's financial performance and operational highlights—is characteristic of an Earnings Release (ER). While it contains annual financial data, it is presented as a press release announcing those results, rather than the comprehensive, audited 10-K filing itself. Since it explicitly details the financial results for the full year (2020), it fits the 'Earnings Release' (ER) category better than a general 'Interim Report' (IR) or a 'Report Publication Announcement' (RPA), as the core content is the results summary, not just an announcement that a report is available. The document length (16,979 chars) is substantial, suggesting it contains more than just a brief announcement. FY 2020
2021-03-31 French
Franchissement de seuils
Major Shareholding Notification Classification · 1% confidence The document is titled "Déclaration de franchissement de seuils (article L. 233-7 du code de commerce)" which translates to 'Declaration of crossing thresholds (Article L. 233-7 of the Commercial Code)'. It explicitly states that the company KGA crossed below the 5% threshold of capital and voting rights of LYSOGENE on February 15, 2021. This type of mandatory disclosure regarding changes in significant share ownership thresholds directly corresponds to the definition of Major Shareholding Notification (MRQ). The document is short and contains the core notification details.
2021-02-19 French
Informations privilégiées / Information sur chiffre d’affaires annuel
Earnings Release Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and its primary focus is announcing the company's cash position as of December 31, 2020. This type of announcement, which provides key financial highlights (cash balance) for a specific period (year-end 2020) but is not the full, comprehensive report (like a 10-K or IR), aligns best with the definition of an Earnings Release (ER). Although it is a cash position update rather than a full P&L/Balance Sheet release, in the context of these specific codes, ER is the most appropriate fit for an initial, high-level financial results announcement. The document length (5188 chars) is substantial enough to be the release itself, not just a notification (RPA/RNS). FY 2020
2021-02-17 French
Inside Information / Information on annual revenues
Earnings Release Classification · 1% confidence The document is titled "Lysogene Reports its Cash Position as of 31 December 2020" and provides key financial highlights (cash balance) and commentary from the CFO, dated February 17, 2021. This format—a press release announcing key financial figures for a specific period (year-end 2020) without being the full, comprehensive annual report (10-K) or a detailed interim report (IR)—is characteristic of an Earnings Release (ER). It focuses on the immediate results announcement rather than a detailed management discussion (MDA) or a full financial statement filing. The length (under 5,000 characters) also suggests it is an initial announcement rather than a full report. FY 2020
2021-02-17 English
Inside Information / Other news releases
Earnings Release Classification · 1% confidence The document is explicitly titled 'PRESS RELEASE' and details biomarker data from an ongoing clinical trial (AAVance) presented at a scientific symposium (WORLDSymposium™ 2021). It provides key results, quotes from management, and information about the trial and the company. This format is characteristic of an Earnings Release (ER) or a general press release announcing significant operational/clinical updates. Since it is a press release announcing specific clinical data and not a comprehensive quarterly/annual financial report (10-K or IR), nor a transcript (CT), the most appropriate classification is Earnings Release (ER), as these often include operational highlights alongside any financial context, or sometimes serve as the primary vehicle for non-financial material news. Given the focus on clinical data presentation, it fits best under ER as a major company update, although RNS is a possibility if it were purely regulatory. However, ER is often used for major scientific/operational announcements by biotech/pharma companies. FY 2021
2021-02-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.